Howard Chan
NHMRC Clinical Trials Group, NSW, Australia
- This delegate is presenting an abstract at this event.
Presentations this author is a contributor to:
A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: The P3BEP Trial (ANZUP 1302) (#266)
3:00 PM
Howard Chan
Posters1
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer: ENZARAD (ANZUP 1303) (#273)
3:00 PM
Scott G Williams
Posters1
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304) (#269)
3:00 PM
Ian Davis
Posters1
Randomised phase 3 double-blind placebo-controlled trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasound-guided prostate biopsy (Pain-Free TRUS B): ANZUP 1501 (#270)
3:00 PM
Ian Davis
Posters1
Randomised phase 3 trial of the addition of Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer(ANZUP 1301) (#267)
3:00 PM
Howard Chan
Posters1
Timing and patterns of referral to palliative care for patients with metastatic non-small cell lung cancer (NSCLC) in South Western Sydney Local Health District (SWSLHD). (#151)
3:15 PM
Peey-Sei Kok
Best of the Best Posters - Clinical & Health services research